| Code | CSB-RA004888MB9HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to RD-129, targeting CD19, a transmembrane glycoprotein exclusively expressed on B cells throughout most stages of B-cell development. CD19 functions as a critical co-receptor in the B-cell receptor complex, lowering the threshold for B-cell activation and playing an essential role in B-cell proliferation, differentiation, and antibody production. Due to its restricted expression pattern and persistence on malignant B cells, CD19 has become a pivotal biomarker in hematological malignancies, particularly B-cell lymphomas, acute lymphoblastic leukemia, and chronic lymphocytic leukemia.
RD-129 is a well-characterized reference antibody widely utilized in B-cell research and immunological studies. This biosimilar provides researchers with a reliable tool for investigating B-cell biology, immune response mechanisms, and B-cell-related pathologies. The antibody supports various research applications exploring CD19-mediated signaling pathways, B-cell development, and the role of CD19 in autoimmune disorders and cancer immunology.
There are currently no reviews for this product.